Similar results have also been reported for tumor models of breast (TUBO), colon adenocarcinoma (MC38) [29], head and neck squamous cell carcinoma (B4B8, LY2) [61], and intracranial glioma (GL261) [60], where concurrent administration of RT and anti-PD-L1 demonstrated improved tumor protection (see Table 1a for the details). The gene discussed is CD274; the disease is neoplasm.